Cardinal Health Inc: Form 10-Q for the period ended Mar 31, 2024
Filed with the SEC on May 2, 2024 and accepted by EDGAR at May 2, 2024, 08:47 ET.
Sections
No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-01-01 to 2024-03-31 | $54.91bn | us-gaap:Revenues |
| Revenue | 9 months2023-07-01 to 2024-03-31 | $167.12bn | us-gaap:Revenues |
| Cost of revenue | 3 months2024-01-01 to 2024-03-31 | $52.96bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2023-07-01 to 2024-03-31 | $161.56bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-01-01 to 2024-03-31 | $1.95bn | us-gaap:GrossProfit |
| Gross profit | 9 months2023-07-01 to 2024-03-31 | $5.56bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2024-01-01 to 2024-03-31 | $1.28bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2023-07-01 to 2024-03-31 | $3.76bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-01-01 to 2024-03-31 | $367.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-07-01 to 2024-03-31 | $835.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-01-01 to 2024-03-31 | $33.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2023-07-01 to 2024-03-31 | $55.0m | us-gaap:InterestExpense |
| Income tax | 3 months2024-01-01 to 2024-03-31 | $82.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-07-01 to 2024-03-31 | $186.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-01-01 to 2024-03-31 | $258.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-07-01 to 2024-03-31 | $616.0m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months2024-01-01 to 2024-03-31 | 245,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-07-01 to 2024-03-31 | 247,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-07-01 to 2024-03-31 | $1.69bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-07-01 to 2024-03-31 | $318.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2023-07-01 to 2024-03-31 | $377.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2023-07-01 to 2024-03-31 | $750.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-03-31 | $3.72bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $35.73bn | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $45.88bn | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $36.31bn | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2024-03-31 | −$3.27bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000721371-24-000038. Last ingested by Listed: Nov 5, 2026, 12:30 ET. Listed shows no prices and gives no investment advice.